CAPRICOR THERAPEUTICS, INC. (CAPR) — Current Report

AI-Powered SEC Filing Analysis

Latest Current Report Filed: 2026-05-12

Key Insights

Capricor Therapeutics announced Q1 2026 financial results on May 12, 2026, but the actual financial metrics and operational performance details are contained in the attached press release (Exhibit 99.1), which is not included in this filing excerpt.
The company is not classified as an emerging growth company, indicating it has passed the size thresholds that would qualify for reduced reporting requirements under securities regulations.
Linda Marbán, Ph.D., acting as Chief Executive Officer, signed the 8-K filing, confirming current leadership and authorized company operations as of the filing date.

Want the newest filings?

This analysis covers the filing from 2026-05-12. New 10-K, 10-Q and 8-K filings are analyzed the moment they are released — exclusively in the app.

Download on the App Store Open in app →

Earlier Current Report filings

Filed: 2026-05-07

Capricor filed a lawsuit against Nippon Shinyaku and its U.S. subsidiary NS Pharma alleging fundamental pricing flaws and material breach of the January 2022 Commercialization and Distribution Agreement for Deramiocel, seeking rescission and the right to distribute directly or through alternative distributors.
The company claims NS failed to adequately prepare for commercial launch of Deramiocel (a DMD treatment), suggesting potential delays or inadequate commercialization efforts that could impact revenue realization and patient access.
This legal action represents a significant dispute over a key commercial partnership, with potential outcomes including loss of the distribution agreement, recovery of distribution rights, and preliminary injunctive relief, creating material uncertainty around the product's U.S. commercialization strategy.

Filed: 2026-03-12

Capricor Therapeutics reported its Q4 2025 and full year 2025 financial results, which provide an update on the company's financial performance and operational progress.
The company's cash position and funding levels appear sufficient to support its ongoing clinical development programs and operations, which is a positive sign for investors.
There were no significant leadership changes or material agreements announced in this 8-K filing, indicating a relatively stable period for the company.

Filed: 2026-03-10

The FDA has lifted the previously issued Complete Response Letter and resumed review of Capricor's Biologics License Application for Deramiocel, an investigational cell therapy for Duchenne muscular dystrophy cardiomyopathy. This is a positive development as it moves the drug candidate closer to potential approval.
The BLA submission has been classified as a Class 2 resubmission, indicating that the FDA considers the application to be a relatively straightforward review process with a target action date of August 22, 2026.
Capricor provided forward-looking statements cautioning investors about the risks and uncertainties associated with the BLA review process, including known and unknown factors that could impact the company's actual results.

Other reports for CAPRICOR THERAPEUTICS, INC.

Insider Trading Quarterly Report Annual Report

Important Information

AI-generated analysis is for informational purposes only. Always read original SEC filings and consult with qualified professionals before making investment decisions.